“In lung cancer, the fragmentation of the diagnostic process, the movement from one laboratory to another, can create major problems both in terms of reporting times and identification of markers, but also because the absence of the anatomopathologist leads to information wrong times “. Thus Renato Franco, coordinator of the Italian study group of Pleuropulmonary Pathology, of the Italian Society of Pathological Anatomy and Diagnostic Cytopathology, spoke during the online meeting “New strategies for the fight against lung cancer”, promoted by The European House Ambrosetti with the non-conditioning contribution of Amgen, dedicated to the innovative Ngs (Next Generation Sequencing) tests, which allow a simultaneous evaluation of dozens of genetic alterations on non-small cell lung cancers (Nsclc).
“In these cases, the absence of a mutation may not be linked to the absence of a real mutation – explained the expert – but to the absence of a mutation on the tumor material to which the marker has been applied, the ideal would be that these procedures take place in an articulated way, in structures of pathological anatomy where the diagnosis of molecular alterations is also made, with the anatomopathologist who must still have a central role ”.